GLP-1 drugs and PCOS: what the studies actually show

What did @the.pcoscollective actually say?

The creator argues that GLP-1 receptor agonists, like semaglutide and tirzepatide, weren't designed for PCOS but may help with symptoms beyond weight loss, including insulin resistance, testosterone levels, cycle regularity, and even pregnancy rates. They cite a "2025 meta-analysis" showing GLP-1 users had more regular cycles and higher natural pregnancy rates compared to metformin users.

To their credit, they frame GLP-1s as off-label for PCOS, acknowledge variable results, and flag side effects like nausea and nutritional gaps. They also avoid the trap of calling these drugs a cure. The framing is more responsible than most TikTok content on this topic. But some specific claims need scrutiny, particularly the testosterone reduction and that metformin comparison.

Does the science back this up?

Partially, yes. The insulin sensitivity claims are reasonably well-supported. Several trials and systematic reviews confirm GLP-1 receptor agonists improve fasting insulin and HOMA-IR scores in women with PCOS. A 2023 systematic review by Dong et al. in Frontiers in Endocrinology found semaglutide and liraglutide reduced fasting insulin and improved metabolic markers in PCOS populations.

The testosterone and SHBG claims have some support too, though the picture is messier. Studies like Elkind-Hirsch et al. (2022, Obesity Science and Practice) found modest reductions in free androgen index with GLP-1 treatment, but results vary considerably by drug, dose, and baseline weight loss. Much of the hormonal improvement appears to track with weight loss itself, not a direct drug mechanism.

The 2025 meta-analysis on cycle regularity and pregnancy rates is harder to evaluate without a specific citation. Research in this area is active, and plausible studies exist, but the claim as stated cannot be independently verified from public databases at the time of writing.

What did they get wrong (or right)?

The creator says GLP-1s are "effectively then metformin," which is an overstatement that deserves a flag. Metformin and GLP-1 receptor agonists work through different mechanisms. Metformin primarily reduces hepatic glucose output and has a decades-long safety record in PCOS. GLP-1s act on pancreatic beta cells, gut motility, and appetite centers. Calling one "more effective" than the other for PCOS specifically goes beyond what current head-to-head evidence supports.

They also state GLP-1s were "improved for some individuals with a BMI of over 35," which is an imprecise description of the regulatory pathway. Semaglutide (Wegovy) was approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. The 35 cutoff isn't accurate here.

What they got right: framing GLP-1s as off-label for PCOS, noting side effects, and pushing back on the idea that weight loss is the only outcome worth discussing. That's a better framework than most creators apply.

What should you actually know?

PCOS is not a single condition with a single driver. Roughly 70-80% of people with PCOS have some degree of insulin resistance, but not all do, and hormonal profiles vary widely. A GLP-1 agonist might meaningfully shift symptoms for someone with significant insulin resistance and elevated androgens, and have a much smaller effect for someone without those features.

GLP-1 receptor agonists remain off-label for PCOS in the US and UK. That isn't a reason to avoid them, but it does mean prescribing decisions should involve a clinician who knows your specific labs and history, not a TikTok series. If you're already on a GLP-1 for another indication and also have PCOS, your symptom response may differ from someone using it for weight loss alone.

• Ask your provider specifically about your androgen levels, insulin markers, and cycle history before framing GLP-1s as a PCOS treatment.
• Nutritional gaps from reduced appetite are a real concern, particularly for B12, iron, and folate, especially relevant if fertility is part of your goals.
• The pregnancy rate comparisons with metformin are intriguing but preliminary. Do not use this as a basis for stopping metformin without medical guidance.